Clever Culture Systems Ltd
16 Anster St
Adelaide SA 5000
www.cleverculturesystems.com

CLEVER CULTURE SYSTEMS

ASX:CC5

UPDATED COMPANY PRESENTATION

Adelaide, Australia, 25 June 2025: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) (**CCS** or the **Company**), is pleased to share an updated Company Presentation. The presentation will be uploaded to the Company website.

Approved for release by the CCS Board.

– ENDS –

About Clever Culture Systems
Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading. The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

Clever Culture Systems
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@cleverculturesystems.com

ASX: CC5

AI-powered microbiology

Revolutionising microbial quality control in pharmaceutical manufacturing

Brent Barnes, CEO and Managing Director
June 2025



CLEVER CULTURE SYSTEMS

Disclaimer

This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct.

Given these uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors, risk and uncertainties including, without limitation, risks associated with estimating potential quantity and timing of sales, risks associated with medical device development and manufacture, risks inherent in the extensive regulatory approval processes mandated by regulatory authorities, delays in clinical trials, future capital needs, general economic uncertainly and other risks detailed from time to time in the Company's announcements to the ASX.

Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.

All reasonable efforts have been made to provide accurate information, but the Company does not undertake any obligation to release publicly any revisions to any "forward-looking statement" to reflect events or circumstances after the date of this presentation, except as may be required under applicable laws. Recipients should make their own enquiries in relation to any investment decisions from a licensed investment advisor.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

CLEVER CULTURE SYSTEMS

Technology

APAS® Independence

Automated reading, interpretation and reporting of microbial growth on culture plates

Revolutionising pharma Microbial QC testing

Cutting edge AI technology
Machine learning for microbiology applications

Demonstrated performance
Extensive scientific data, faster than microbiologist

Significant market opportunity
Focus on global pharma manufacturers

Market trends driving shift to automation
Industry seeking to remove manual processes



ASX: CC5

Market leader

- APAS Independence validated culture plate reading technology
- First and only end-point reader deployed in routine drug manufacturing

Growing customer base

- 13 instruments sold to pharmaceutical customers since launch in Mar-24
- Early sales achieved in anticipation of contact plates development (Q1 FY26)
- Engaged with 14/20 of the largest global pharmaceutical companies[1]

Financial stability

- Product sales transition Company to profitability
- Growing installed base builds platform for ARR growth

1. Top 20 Pharma based on annual revenue

Environmental Monitoring is a highly regulated process

- Critical and mandatory process to maintain drug product quality and safety
- Measures whether the manufacturing facility is operating in a state of control
- Culture plates used for monitoring of air, surfaces, personnel and water during drug manufacture daily

CLEVER CULTURE SYSTEMS

Problem

Millions of culture plates are manually read and reported annually during pharmaceutical manufacturing

Incorrect results costly

High cost of failure

Up to US$1bn lost revenue[1]

Failed results in pharmaceutical manufacturing can lead to substantial revenue losses. Catastrophic impact is patient death

Regulatory scrutiny

116% regulatory increase[2]

Rise in regulatory observations to drug establishments creates compliance challenges

Inefficient

Up to 98% zero growth plates[3]

Millions of plates reviewed annually, majority of plates have no growth yet require dual analyst verification, wasting resources

1. www.researchandmarkets.com, Global Pharmarcetuicals Market Report 2021: Covid-19 Impact and Recovery to 2030.
2. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
3. https://www.cleverculturesystems.com/scientific-library/apas-pharmaqc-ai-culture-plate-reading

Digital disruption

APAS INDEPENDENCE



Solution: APAS

Automated Plate Assessment System

Cutting edge AI technology
Machine learning for microbiology applications

Demonstrated performance
Extensive scientific data, faster than microbiologist

Improved data integrity
Automatic data trails and audit reports

Easy integration and user operation
Simple plug and play technology

Environmental monitoring today

Mandatory process in every pharmaceutical manufacturing facility globally

Culture plates

Environmental monitoring

Cleanrooms
(pharmaceutical manufacturing)

Incubation
(3-7 days)

Critical decision point

Culture plate reading, reporting. Result to release pharmaceutical product

No Growth
➔ Batch release

Growth detected
➔ Batch held
➔ Investigation

Environmental monitoring with APAS

Mandatory process in every pharmaceutical manufacturing facility globally

Culture plates

Environmental monitoring

Cleanrooms
(pharmaceutical manufacturing)

Incubation
(3-7 days)

Critical decision point

Automated culture plate reading

APAS INDEPENDENCE

No Growth >90%
➔ Batch release automatically

Growth detected ~2-10% reviewed manually

Opportunity

Clever Culture Systems.

AU$2.8B TAM[1]

Total Addressable Market for aseptic manufacturing microbiology testing. Pharma companies are investing in expanding manufacturing facilities and automation

14 of Top 20[2]

Sales pipeline includes largest pharmaceutical manufacturers globally. Opportunity for multi-instrument sales, establishes industry credibility.

>40 qualified leads

Sales momentum building. Qualified opportunities represent **~$75 million** in upfront sales and **$15 million** per annum in recurring revenues.[3]

1. Global Pharmaceuticals & Medicine Manufacturing; IBISWorld Industry Report + internal company analysis
2. Top 20 Pharma based on annual revenue
3. Sales Pipeline Value estimated on potential number of APAS instruments across current active customers

Pharmaceutical manufacturing: Attractive market for optimisation

Roche

Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years

USD 50 billion commitment includes new state-of-the art research and development (R&D) sites, new and expanded manufacturing facilities in...

22 Apr 2025

Business Wire

Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers' Manufacturing

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will invest an additional $2 billion in the United States...

24 Apr 2025

Genetic Engineering and Biotechnology News

BMS Commits $40B over Five Years to U.S. R&D, Manufacturing

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the...

1 month ago

Up to AU$1.5m revenue per APAS Independence sale[1]

Includes up-front Capex and Annual Recurring Revenue (ARR) streams

Product / Service	Description	Revenue Model	Approx. Split
APAS® Independence	Laboratory Instrumentation	Upfront Capex *(inc. financing options)*	40%
APAS Apps®	AI Software Licence	ARR	40%
APAS Service[2]	Support and maintenance services	ARR	15%
Implementation Services	Instrument connectivity, technical data and validation support	One-off	5%

1. Typical revenue over 7 years (expected life of instrument)
2. Third-party service provider / distributor expected to provide service

Different automation approach

Incubation and reading technologies

- Requires continuous reading between incubator and imaging platform
- Incubation size restricts volume capacity (60-132 plates per day capacity)

3P System – bioMerieux
(Interscience OEM)

Incubator capacity **300** plates
~60 plates per day[1]

Growth Direct – Rapid Micro Biosystems
(NASDAQ RPID)

Incubator capacity **~660** plates
~132 plates per day[1]

1. Daily capacity assumes industry standard 5-day incubation

APAS Independence: end point reader

APAS delivers scale

- 1 APAS instrument automates 1,600 plates per day
- Customers use their existing low-cost, high-volume incubators

Go-to-market strategy

Land and expand

Land a single instrument sale. APAS expands to become the standard across customer global sites

Top-20 largest pharma

Focus on the largest biologics manufacturing customers who have many global sites, establishing credibility across industry

Customer advocacy

Blue-chip customers, AstraZeneca, Bristol Myers Squibb publishing data

AstraZeneca Case Study

Enterprise customer – Standardisation across multiple global sites

- ~1,000 plates per day at large AZ sites
- >98% of plates are negative
- Occasionally humans make mistakes
- APAS resolves data integrity challenges



AstraZeneca

9 instruments purchased and installed

- Multiple global manufacturing locations
- Advocates of technology presenting at multiple conferences
- Validated technology for routine use

Contact plates launch: unparalleled advantage

Launch Q1 FY26 to accelerate sales pipeline covering major tests

Settle Plates ~50% used

Contact Plates ~50% used

Automating more tests in Environmental Monitoring

Passive and Active Air Sampling, Personnel Monitoring, Surface Sampling

- Unlocks opportunity to convert and expand customer sales pipeline
- Current pipeline 40+ qualified leads built based on APAS automating ~50% workflow today, with knowledge of contact plate product pipeline being delivered
- Contact plate launch to automate majority of Environmental Monitoring tests

APAS Placements



28 instruments installed globally

Experienced

Board and Management

Focused on expansion into pharmaceutical manufacturing industry

- Board and Management shareholding 20%+
- International experience with healthcare, technology and pharmaceutical manufacturing expertise
- Extensive public listed ASX experience in micro-cap and high-growth companies

Brent Barnes
CEO and MD, AU
Aug-16 start

Rebecca Wilson
Chair, AU
Jul-23 start

Dan Hill
NED, AU
Dec-23 start

Ian Wisenberg
NED, US
Oct-24 start

Ray Ridge
CFO and CoSec, AU

Corporate Overview

Transitioning to profitability



Key Statistics (Closing Price on 20 June 2025)	
Share Price	$0.017 per share
Shares on Issue	1.77 billion
Top-20 Shareholding	65%
Market Cap.	$30.0 million
Listed options (CC5OA)	~400 million expiring 15-11-25 at $0.008

Financials (AUD)	
Cash & Receivables (31 March 25)	$2.2 million Cash $3.6 million Receivables *Up to $3.2m additional cash in flow from options vesting in November 24*
Annual Cost Base	$4.2m expected *(less R&DTI refund & recurring income)*
Est. Breakeven Sales	*~ 11 APAS instruments*
SAFA Loan Facility	$1.0 million outstanding *(low interest rate, interest only until 2026)*

Pharmaceutical sales transition Company

Blue-chip customers underpin path to profitability

Commercial

AstraZeneca Bristol Myers Squibb®

Global pharmaceutical customers bought and standardising APAS for environmental monitoring. Substantial market opportunity for APAS to become the new standard

13 APAS instruments sold to pharma since launch in March 2024

Corporate

HY25 maiden profit $1.1m, driven by product sales of $3.8m

High-margin recurring revenue >$0.5m across install base of 28 instruments

Mar-25 cash and current receivables of $5.8 million

Product expansion

New environmental monitoring test for contact plates expands APAS utility for customers

Increases market opportunity and **increases ARR** for APAS

Launching Q1 FY26

Outlook



New sales and placements with Top-20 pharma companies
Sets established userbase for future sales

Growth in customers using the technology in routine operations
Drives growth in recurring revenues

Contact plate application provides unique value proposition for customers
Expands overall APAS market opportunity

Financial outlook: Expectation for maiden FY25 transition to profitability
Target to transition to sustainable profitability